acamprosate + escitalopram

Acamprosate + escitalopram is a combination of two pharmaceutical agents used experimentally and in clinical trials for the treatment of individuals with comorbid alcohol use disorder (AUD) and major depressive disorder. Acamprosate is an agent approved for maintaining abstinence in alcohol-dependent patients; it works by modulating glutamate and GABA neurotransmitter systems, particularly acting as an NMDA receptor antagonist and GABA_B receptor inhibitor, thereby stabilizing neurochemical imbalances caused by chronic alcohol use. Escitalopram is a selective serotonin reuptake inhibitor (SSRIs) antidepressant that increases synaptic serotonin levels by inhibiting the serotonin transporter (SERT), both at orthosteric and allosteric sites, leading to enhanced serotonergic neurotransmission. The rationale for combining these drugs lies in their complementary mechanisms—acamprosate targets neuroadaptations associated with AUD while escitalopram addresses depressive symptoms—potentially improving outcomes in patients suffering from both conditions[1][5]. Preclinical studies have shown that this combination can reduce ethanol intake more effectively than either drug alone, especially under stress-induced depression models[1][3]. Clinical trials are ongoing to assess efficacy in humans[2][5].